Page 120 - Molecular features of low-grade developmental brain tumours

Sample
Age (years)
Gender
Mutation
Location of tumour
Epilepsy
Age of onset
Seizure freq.
AED
mTOR
4
Gene
Forward (5’->3’)
Reverse (5’->3’)
CHAPTER 4
Supplementary information
Supplementary Table 1. Summary of clinicopathological features of TSC patients.
male TSC2
female TSC2
male TSC2 male TSC1
Supplementary Table 2. Primer list.
LAMTOR1 LAMTOR2 LAMTOR3 LAMTOR4 LAMTOR5 EEF1A1 (EF-1α)
Tuber1 4 Tuber2 10
months Tuber3 2 Tuber4 8
AML1 48
AML = angiomyolipoma, AED = antiepileptic drugs.
frontal cortex
frontal cortex
frontal cortex frontal cortex
kidney
yes 2 >50 yes no months per
month
yes 38yes no
days per day
yes 1 unknown yes no month
yes 91yes no months per
2 days
no --no no
female TSC1
ggagcagcatgagtacatgg acccaggtgctaagccaag ctgaagtgacagcggagaga tcttggcttgctgctagaact acaaggacttaatctgggttgc atccacctttgggtcgcttt
ggtggcagcttcttccaat ccctcgttattcagcagca tcgcaggatcaatctccac cacagctcagagtccccaag ggttagcttagctgcttgctg ccgcaactgtctgtctcatatcac
The following tables can be downloaded via https://www.ebi.ac.uk/biostudies/studies/ S-EPMC6935755?xr=true (files: Supplementary_Data1, Supplementary_Data5 and Supplementary_Data6).
Supplementary Table 3. Pathways enriched in SEGA compared to control tissue.
Supplementary Table 4. Differentially expressed genes in SEGA compared to control tissue. Supplementary Table 5. Differentially expressed small RNAs in SEGA compared to control tissue.
118